AI CuratorAI-generated

Research summary · 2 h ago

AI summary · not yet reviewedHuman studyNot reportedPublished in a peer-reviewed journal

EBV Serologic Profiles in Human Patients with MS and MOGAD

In a study of patients with Multiple Sclerosis (MS) and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), nearly all participants were EBV seropositive. However, MS patients exhibited significantly higher EBNA1 IgG levels compared to MOGAD patients and controls, with notable variations in the frequency of elevated EBNA1 IgG levels. MOGAD patients had lower VCA IgG levels than controls.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42956321)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Human efficacy: Not established from this source
Mechanism: Not reported
Evidence strength: Not graded
Outcome: Not reported

Why it matters

These findings suggest a distinct EBV antibody profile in MS compared to MOGAD and healthy controls, which may offer insights into the possible immunological involvement of EBV in MS pathology.

What this does not prove

The study does not establish causation and findings may not be applicable outside the Korean population.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Not reported
Participants / samples: Not reported
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-10-28
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified
Biological target: Not reported
Pathway: Not reported
Population: Patients with MS, MOGAD, and untreated tumor controls
Size of effect: Not reported
Secondary endpoints: Not reported
MRI endpoints: Not reported
Biomarkers: Not reported
Safety: Not reported

Original sources

Primary evidenceEpstein-Barr Virus Serologic Profiles in Multiple Sclerosis and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. ↗DOI: 10.1212/nxi.0000000000200674

Supporting passages (9)

subjectsHuman

publication date2026-10-28

comparatorMETHODS: We analyzed MS (n = 130), MOGAD (n = 125), and untreated tumor controls without known EBV association (n = 132).

primary endpointEBV serostatus and antibody titers

findingsEBNA1 responses differed across groups, with the frequency of EBNA1 IgG levels exceeding the upper reportable limit (>600 U/mL) being highest in MS, compared with MOGAD and controls (66.2% vs 33.6% vs 43.9%; p < 0.001).

populationMETHODS: We analyzed MS (n = 130), MOGAD (n = 125), and untreated tumor controls without known EBV association (n = 132).

limitationsTitle: Epstein-Barr Virus Serologic Profiles in Multiple Sclerosis and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

peer reviewedPublication types: Journal Article

subjectsMeSH terms: Humans; Multiple Sclerosis; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Female; Adult; Male; Herpesvirus 4, Human; Epstein-Barr Virus Infections; Middle Aged; Antibodies, Viral; Epstein-Barr Virus Nuclear Antigens; Republic of Korea; Antigens, Viral; Immunoglobulin G; Capsid Proteins; Young Adult

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.